PUMA BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.02 USD | +2.87% |
|
+0.20% | +15.94% |
Presentation Operator MessageOperator (Operator)Good afternoon. My name is Camilla, and I will...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
5.02
USD
Average target price
4.333
USD
Spread / Average Target
-13.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.94% | 242M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PBYI Stock
- News Puma Biotechnology, Inc.
- Transcript : Puma Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
